It is unknown whether targeted temperature management (TTM) (32-34°C) improves 84 survival and reduces brain injury for infants and children after out-of-hospital cardiac arrest 85 (OHCA) (1). TTM is the active treatment of inducing and maintaining a specific body 86 temperature for a specific duration of time attempting to improve health outcomes (2) . 87 Randomized controlled trials in the 2000s renewed interest in 12-24 hours of TTM (32-34°C) 88 as a therapeutic intervention in adult survivors of OHCA (3, 4) and for 72 hours in neonates 89 after birth asphyxia (5). The International Liaison Committee on Resuscitation (ILCOR) 90 introduced guidance in April 2006 that TTM (32-34°C) may be: 1) beneficial for adolescents 91 who remain comatose following resuscitation from sudden, witnessed, ventricular fibrillation 92 OHCA and 2) considered for infants and children who remain comatose following 93 resuscitation from cardiac arrest (6). More recent adult studies confirm a role for 24 hours of 94 TTM but show that a higher temperature target (TTM 36°C) produces similar results to a 95 lower target (TTM 33C) (7) . The randomized control trials of Therapeutic Hypothermia 96 after Pediatric Cardiac Arrest (THAPCA studies) of OHCA (NCT00878644) and in-hospital 97 cardiac arrest (NCT00880087) investigating TTM at 33°C for 48 hours versus TTM at 98 36.7°C are on-going (8, 9) .
99
Paediatric retrospective studies of TTM have been limited (10-12). Two studies showed no 100 difference in survival outcome with TTM (33-34°C) versus the institutions usual standard 101 temperature management (STM). The usual STM practice was to maintain normothermia by 102 avoiding hyperthermia (<38°C), but frequently did not involve using active temperature 103 control devices (4, 10).These studies included small numbers of OHCA patients and 104 contained very unbalanced groups with regards illness severity, with greater use of TTM (32-105 34) in the more severe group. One recent study from Taiwan did show a statistically 106 significant increase in survival after 72 hours of TTM (33-34°C) (12). However, the OHCA A c c e p t e d M a n u s c r i p t 6 population was small and differences between healthcare systems may limit generalizability.
108
These studies identified that inadvertent overcooling (<32°C) and hyperthermia (>38°C) 109 increased the risk of worse outcome.
110
The ILCOR TTM (32-34°C) guidance was adopted in our paediatric intensive care unit 111 (PICU) in 2007. TTM (32-34°C) use has developed iteratively and culminated in the use of 112 servo-controlled temperature management devices and a standardized protocol. The aim of 113 this study was to assess evolution, safety and efficacy of TTM (32-34°C) in a tertiary PICU 114 and compare to usual institutional standard temperature management (STM) (aiming to avoid 115 hyperthermia; >38⁰C).
116

PATIENTS AND METHODS
117
The hospital research committee (Institutional Review Board) approved the study and waived 118 the need for consent given the observational nature of the study. Case records were reviewed with data-verification at inputting and analysis stage. Patients 129 were divided into two groups, targeted temperature management (TTM 32-34°C) and 130 standard temperature management (STM). The use of TTM was defined a priori as 131 documented active TTM to maintain a core temperature between 32-34°C. STM group 132 included patients whose temperature was maintained at normothermia using rescue 133 temperature controlling measures to avoid hyperthermia (>38°C). (Blanketroll II, Cincinnati Sub Zero, Ohio, USA) to reduce temperature between 32 to 34⁰C 154 for 24 hours followed by controlled rewarming, by 0.5⁰C every 2 hours, to 37⁰C.
119
Settings and participants
155
Neuromuscular blocking drugs were used to prevent or treat shivering in conjunction with 156 intravenous sedation and analgesia (morphine and midazolam). Patients were invasively 157 ventilated with arterial blood gases monitoring. Standard 'neuroprotective' PaCO 2 target 158 range was 4.5 to 5.0kPa. Inotropes were used to maintain age appropriate blood pressure. and was initiated in 34/48; 71% of patients (p <0.0001, Fig. 1 ).
184
A c c e p t e d M a n u s c r i p t 10 There were no differences in age, sex or weight in patients receiving either treatment (table   186 1). TTM (32-34°C) was used more frequently in patients whose cause of arrest was unknown 187 and less in patients presenting with cardiac arrest associated with trauma (including traumatic 188 brain injury). Prevalence of OHCA occurring in the home or being witnessed was similar for 189 patients receiving TTM (32-34°C) and STM (<38°C) ( Overall survival to hospital discharge of patients admitted to PICU after OHCA was 29% 244 (21/73) (Table 3 ). Survival was not significantly different between TTM (32-34°C) and STM 245 (<38°C) treatment groups (34% vs. 23%; p=0.28). (Table 3) . There were a similar proportion of patients in both groups who had 250 withdrawal of life sustaining intensive care support prior to death. The aim of this study was to assess the evolution, efficacy and safety of TTM (32-34°C) in (20); however, rapid reduction in temperature has also been associated with worse 273 neurological injury (21). Unintentional overshoot in temperature to <32°C occurred in 11% 274 of patients, similar to the 15-17% rate in other retrospective studies (4, 10) but significantly 275 less than the 75% reported by Topjian et al (22) . Increased mortality has been reported in 276 subgroups who are overcooled (6) although the causal association has not been established.
277
The use of servo-controlled cooling units, rather than manual temperature control (e.g. ice-278 packs), may account for the reduction in unintentional overshoot.
280
Controlled rewarming and the avoidance of overshoot hyperthermia (>38°C) are required to 281 prevent hemodynamic instability, rapid electrolyte changes and worsening of neurological 282 injury (23, 24). Patients were rewarmed at a median rate of 0.3°C/hour, but only 32% re-283 warmed less than or equal to 0.25°C/hour and of concern, 39% experienced hyperthermia.
284
The optimal rewarming rate after TTM (32-34°C) in humans has not been established with a A c c e p t e d M a n u s c r i p t 14 tendency to decrease rates over the last 10 years (25). Improvements to rewarming strategies 286 and prolonged active control of normothermia may be required to avoid rebound 287 hyperthermia as exposure to hyperthermia in the post-hypothermia phase has also been 288 associated with increased mortality and poor neurological outcome (26).
290
Reduction in core temperature in humans is known to be associated with a concomitant 291 reduction in heart rate in sedated patients (27) . Bradycardia and hypotension is therefore a 292 consistent finding in studies of TTM (32-34°C), irrespective of underlying disease process 293 (10, 11, 27) . Although bradycardia is believed to not require treatment, the management of 294 hypotension is more controversial. An increase in the proportion of patients with bradycardia 295 and hypotension in the TTM (32-34°C) group was observed. This was associated with 296 increased inotropic support though this did not reach significance. Recently, hypotension in 297 the 1 st 6 hours after ROSC in children has been shown to be associated with higher in-298 hospital mortality and worse neurological outcome (28). In the current study hypotension neuro-imaging investigation to predict outcome after hypoxic ischemic brain injury (33-36).
319
Delayed clearance of sedative drugs alters timing for neurological and brain death testing, 320 prolonging PICU length of stay (37). This effect was observed with a four-fold increase in Neonatal studies after birth asphyxia have supported the recommendations of TTM (33°C) 339 for 72 hours (5). These study populations were carefully selected with a homogenous 340 pathology and severity assessed by predefined stratification criteria. However, the paediatric 341 OHCA population is heterogenous; variable aetiologies, co-morbidities and resuscitation 342 factors limit the ability to extrapolate the neonatal findings to paediatric OHCA.
344
This study has the following limitations. 1) This is a single centre study and is still relatively 345 small despite a seven year data collection period. 2) Data from a single centre may limit the Mean temperature (with 95% confidence intervals for the mean). TTM: targeted temperature management (32-34°C). STM: Standard temperature management (<38°C). 
